Invasive Meningococcal Disease and Vaccines

Öz

Meningococcal diseases continue to have a major public health impact in many countries. Fatality rate of invasive meningococcal disease IMD in pediatric patients is 10 %. At least 75 % of cases of are caused byserogroups A, C, Y, and W-135; thus, IMD potentially is preventable by immu- nization. Plain polysaccharides vaccines for Neisseria meningit have been in use for approximately 20 years, both to prevent invasive disease in high-risk population and to control disease outbreaks. The preferred vaccine for people ages 2-55 years is Meningococcal conjugate vaccine MCV4

Anahtar Kelimeler

• Meningococcal infections,meningococcal vaccines

İnvaziv Meningokok Hastalığı ve Aşıları

Öz

Meningokok infeksiyonları bütün dünyada önemli sağlık sorunları arasında yer almaya devam etmektedir. İnvaziv Meningokok hastalığı çocukluk çağında % 10 oranında ölümcül olabilmektedir. Vakaların % 75’inden serogrup A, C, Y ve W135 sorumludur. İMH aşılama ile önlenebilir bir hastalıktır. İnfeksiyonların önlenmesi için uzun yıllardan beri iki yaşından itibaren uygulanan polisakkarid aşılar risk gruplarında ve salgın kontrolünde kullanılmaktadır. İki-55 yaş arasında tercih edilen aşı, meningokok konjuge aşıdır MCV4

Anahtar Kelimeler

• Meningokok aşıları,meningokok infeksiyonu

Kaynakça

1. 1. Centers for Disease Prevention and Control. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-7):1-10.
2. 2. Bilukha OO, Rosenstein N. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005;54(RR-7):1-21. PMid:15917737
3. 3. Anderson MS, Glode MP, Smith AL. Meningococcal disease, “Feigin RP, Cherr JD, Demmler GJ, Kaplan SL (eds): Texbook of Pediatric Infectious Diseases 5. baskı” kitabında s.1265-1280, Saunders, Philadelphia 2004.
4. 4. Boulton RB, Alder SC, Mottice S, Catinella AP, Byington CL. Invasive meningococcal disease, Utah, 1995-2005, Emer Infect Dis 2007;13(8).
5. 5. Brouwer MC, Read RC, Van de Beek D. Host genetics and out come in meningococcal disease: a systematic review and meta-analysis, Lancet Infect Dis 2010;10:262-74. http://dx.doi.org/10.1016/S1473-3099(10)70045-1
6. 6. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose range study assessing immunogenity and safety of one dose of a new candidate meningococcal serogroups A C, W-135, Y, tctanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of the life and in young children Vaccine 2010;28-744.
7. 7. Ceyhan M, Yıldırım İ, Balmer P, et al. A Prospective study of etiology of childhold acute bacterial meningitis, Turkey, Emer Infect Dis 2008;14:1089-96. http://dx.doi.org/10.3201/eid1407.070938 PMid:18598630 PMCid:2600347
8. 8. Doğancı L, Baysallar M, Saraçlı MA, Hasçelik G, Pahsa A. Neisseria meningitidis W135 Turkey, Emerg Infect Dis 2004;10-936.

9. 9. Badur S, Bakır M. Aşı kitabı. Akademi Yayınevi, Meningokok aşıları, 245-53.
10. 10. Stephens DS, Greanwood B, Brandtzaeg P. Epidemic meningitidis, meningococcaemia and Neisseria meningitidis, Lancet 2007;369:2196. http://dx.doi.org/10.1016/S0140-6736(07)61016-2
11. 11. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010;9:285-98. http://dx.doi.org/10.1586/erv.10.3 PMid:20218857
12. 12. Goria MC, Paiva MV, Salqueiro VC et al. Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008, Enterm Infect Microbiol Clin 2011;29:85-9. http://dx.doi.org/10.1016/j.eimc.2010.07.016 PMid:21345528
13. 13. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002;51(RR-2):1-35.
14. 14. DEPARTMENT OF HEALTH & HUMAN SERVICES FDA/ CBER/OVRR/DVRPA http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM246961.pdf
15. 15. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60:673-80. PMid:411104
16. 16. Roberts J, Bryett K. Incidence of reactions to meningococcal A and C vaccine among U.K. schoolchildren. Public Health 1988;102:471-6. http://dx.doi.org/10.1016/S0033-3506(88)80085-4
17. 17. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines, Vaccine 2009;27(Suppl 2):B30-41. http://dx.doi.org/10.1016/j.vaccine.2009.05.003 PMid:19477560
18. 18. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the 57 Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 2005;54(RR-7):1-21. PMid:15917737
19. 19. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines, Vaccine 2009;27(Suppl 2):B30-41. http://dx.doi.org/10.1016/j.vaccine.2009.05.003 PMid:19477560
20. 20. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Morb Mortal Wkly Rep 2010;59(9):273. PMid:20224545
21. 21. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices (ACIP), 2011, MMWR Morb Mortal Wkly Rep 2011;60(30): 1018-9. PMid:21814165
22. 22. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents, Clin Infect Dis 2009;49(1):e1- 10. http://dx.doi.org/10.1086/599117 PMid:19476428
23. 23. Vesikari T, Karvonen A, Lindbland N, et al. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MenACWY-TT) vaccine in toddlers and children after one year, 6th Annual Meeting of the World Society for Pediatric Infectious Diseases-WSPID, (Abstract 582) Buenos Aires, Argentina, 18-22 November (2009).
24. 24. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years, Vaccine 2009;27(1):161-8. http://dx.doi.org/10.1016/j.vaccine.2008.08.075 PMid:18834910
25. 25. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27 Suppl 2: B51-63. http://dx.doi.org/10.1016/j.vaccine.2009.04.063 PMid:19477562
26. 26. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304. http://dx.doi.org/10.1056/NEJMoa1003812 PMid:21675889
27. 27. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Morb Mortal Wkly Rep 2011;60(3):72- 6. PMid:21270745
28. 28. Dinleyici EC, Ceyhan M. The dynamic and changing epidemiology of meningococcal disease at the country-based level: The experience in Turkey, Expert Rev Vaccines 2012 (in press). http://dx.doi.org/10.1586/erv.12.29 PMid:22827237